This Week in Cell

An international team led by René Bernards, with The Netherlands Cancer Institute and Agendia, explores the genetics of cancer treatment susceptibility and resistance, focusing first on ALK and EGF receptor tyrosine kinase inhibitor therapies. Using an RNA interference screen in a non-small cell lung cancer line carrying an EML4-ALK translocation, the researchers determined that knocking down a gene called MED12 confers resistance to an ALK-inhibiting drug called crizotinib.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.